Reader TTS

Access through your institution Buy or subscribe The introduction of targeted therapies such as vascular endothelial growth factor and mammalian target of rapamycin inhibitors has improved

the outcomes of patients with metastatic renal cell carcinoma (mRCC); however, at the same time, the role of cytoreductive nephrectomy, which was previously widely used in the treatment of

these patients, has become unclear. Now, data from an extensive National Cancer Database Study confirm the continued importance of this surgery in patients with mRCC who are receiving

targeted therapy. On the rationale for this approach, lead authors Maxine Sun and Toni K. Choueiri explain: “previously we knew cytoreductive nephrectomy improved the outcomes of patients

receiving cytokines owing to data from clinical trials. However, we don't have such data following the advent of targeted therapies”. Building on work from a previous study of 201

patients, the outcomes of 15,390 patients receiving targeted therapies with or without cytoreductive nephrectomy for mRCC in the USA between 2006 and 2013 were analysed. Cytoreductive

nephrectomy was performed in 35% of patients included in the database, and the use of this procedure was found to provide survival benefits of 0.7 months and 3.6 months in patients who

survived ≤6 months and ≤24 months, respectively. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this

journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now

Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support REFERENCES * Hanna, N. _ et al_. Survival analyses of metastatic renal cancer patients treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data

base study. _J. Clin. Oncol._ http://dx.doi.org/10.1200/JCO.2016.66.7931 (2016) Download references Authors * Peter Sidaway View author publications You can also search for this author

inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sidaway, P. Cytoreductive nephrectomy improves outcomes in the era of targeted

therapy. _Nat Rev Urol_ 13, 438 (2016). https://doi.org/10.1038/nrurol.2016.127 Download citation * Published: 05 July 2016 * Issue Date: August 2016 * DOI:

https://doi.org/10.1038/nrurol.2016.127 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative